JOSH'S STORY
In February of 2021, Josh’s parents noticed he was getting very pale. What was originally thought to...
Read MoreCell cycle inhibition is one of the most successful targets to reduce proliferation and induce apoptosis in cancer cells. A number of potential molecular targets for novel anticancer drug discovery have been identified in cell cycle control mechanisms. Prominent among these are the regulatory proteins, cyclins and their effector counterparts the cyclin dependent kinases (CDKs). CDK inhibitors currently under investigation include flavopiridol, olomoucine, roscovitine, puvalanol B, the dihydroindolo(3,2-d)(1) benzazepinone kenpaullone, indirubin-3-monoxime and novel diaminothiazoles (Buolamwini J.K, 2000). In recent studies it has been shown that Cyclin Dependent Kinase 6 (CDK6) is one of the best targets to reduce the proliferation of cancers in particular cancers of childhood and early adolescence (Shapiro G. 2006). Despite being ideal target only one specific inhibitor is in clinical trials (PD0332991) and has shown inconsistent result with stabilization of CDK6/Cyclin D complex (Paternot et al, 2014). Based on this oncogene addiction paradigm, we want to test various small molecules (dibenzoyl-methane derivatives)
Grant Award – Kidscan Student Placement (2016 – 2017)
Funding Award – £2000.00
Funding Awarded to – Dr Athar Aziz
Research Location – University of Salford
Lead Researcher – Dr Athar Aziz
In February of 2021, Josh’s parents noticed he was getting very pale. What was originally thought to...
Read MoreWhat a whopper of a night - Friday 20th May, our ambassador Isla's mum Jill and family hosted...
Read MoreWe want to say a huge thank you to Lee Mossop, former Captain of RFL Salford Red...
Read More